摘要
背景：心血管手术后新发心房颤动（AF）与并发症风险增加和住院时间延长有关。确定手术后房颤（POAF）高风险患者可能有助于采取具有临床和经济相关性的预防策略。 目的：本综述的重点是总结心肌纤维化生物标志物（PICP和PIIINP），促纤维化介质（TGF-β1），细胞外基质重塑（MMP-9），心肌舒张（BNP和NTpro-BNP），炎症的研究结果。 （白细胞介素，C-反应蛋白和sCD40L）和心肌坏死（高敏感肌钙蛋白T），生物标志物，可用于临床实践，对POAF风险患者进行分层。 方法：我们搜索了MEDLINE和PubMed的英语语言学习。证据综合基于队列研究，临床试验和荟萃分析数据。还审查了国际临床实践指南。 结果：心脏重塑，心房压力，手术创伤，炎症，氧化应激和交感神经/副交感神经激活等因素与POAF的发展有关。基于POAF发病的多因素机制，一些研究已经研究了一些血清生物标志物的预测价值。迄今为止，有关PICP，PIINP，TGF-β1和sCD40L的临床应用的有希望的初步数据，而关于NT-proBNP，BNP，CRP，IL-6和hs-cTnT的数据存在争议。 结论：尽管一些研究显示了有希望的结果，但在将生物标志物用作临床实践中POAF风险分层的工具之前，需要进行更长期随访的更大规模研究。
关键词: 心房颤动，术后心房颤动，胶原合成，脑利钠肽，白细胞介素，炎症。
[1]
Echahidi, N.; Pibarot, P.; O’Hara, G.; Mathieu, P. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J. Am. Coll. Cardiol., 2008, 51(8), 793-801.
[2]
Villareal, R.P.; Hariharan, R.; Liu, B.C.; Kar, B.; Lee, V.V.; Elayda, M.; Lopez, J.A.; Rasekh, A.; Wilson, J.M.; Massumi, A. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J. Am. Coll. Cardiol., 2004, 43(5), 742-748.
[3]
Ommen, S.R.; Odell, J.A.; Stanton, M.S. Atrial arrhythmias after cardiothoracic surgery. N. Engl. J. Med., 1997, 336(20), 1429-1434.
[4]
Turagam, M.K.; Mirza, M.; Werner, P.H.; Sra, J.; Kress, D.C.; Tajik, A.J.; Jahangir, A. Circulating biomarkers predictive of postoperative atrial fibrillation. Cardiol. Rev., 2016, 24(2), 76-87.
[5]
Manfrini, O.; Bazzocchi, G.; Luati, A.; Borghi, A.; Monari, P.; Bugiardini, R. Coronary spasm reflects inputs from adjacent esophageal system. Am. J. Physiol. Heart Circ. Physiol., 2006, 290(5), H2085-H2091.
[6]
Ahn, H.J.; Sim, W.S.; Shim, Y.M.; Kim, J.A. Thoracic epidural anesthesia does not improve the incidence of arrhythmias after transthoracic esophagectomy. Eur. J. Cardiothorac. Surg., 2005, 28(1), 19-21.
[7]
Almassi, G.H.; Schowalter, T.; Nicolosi, A.C.; Aggarwal, A.; Moritz, T.E.; Henderson, W.G.; Tarazi, R.; Shroyer, A.L.; Sethi, G.K.; Grover, F.L.; Hammermeister, K.E. Atrial fibrillation after cardiac surgery: a major morbid event? Ann. Surg., 1997, 226(4), 501-511.
[8]
Cox, J.L. A perspective of postoperative atrial fibrillation in cardiac operations. Ann. Thorac. Surg., 1993, 56(3), 405-409.
[9]
Gulielmos, V.; Menschikowski, M.; Dill, H.; Eller, M.; Thiele, S.; Tugtekin, S.M.; Jaross, W.; Schueler, S. Interleukin-1, interleukin-6 and myocardial enzyme response after coronary artery bypass grafting - a prospective randomized comparison of the conventional and three minimally invasive surgical techniques. Eur. J. Cardiothorac. Surg., 2000, 18(5), 594-601.
[10]
Spyrou, N.; Khan, M.A.; Rosen, S.D.; Foale, R.; Davies, D.W.; Sogliani, F.; Stanbridge, R.D.; Camici, P.G. Persistent but reversible coronary microvascular dysfunction after bypass grafting. Am. J. Physiol. Heart Circ. Physiol., 2000, 279(6), H2634-H2640.
[11]
Pries, A.R.; Badimon, L.; Bugiardini, R.; Camici, P.G.; Dorobantu, M.; Duncker, D.J.; Escaned, J.; Koller, A.; Piek, J.J.; de Wit, C. Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation. Eur. Heart J., 2015, 36(45), 3134-3146.
[12]
Heper, G.; Korkmaz, M.E.; Kilic, A. Reperfusion arrhythmias: are they only a marker of epicardial reperfusion or continuing myocardial ischemia after acute myocardial infarction? Angiology, 2007, 58(6), 663-670.
[13]
Cenko, E.; Ricci, B.; Kedev, S.; Kalpak, O.; Câlmâc, L.; Vasiljevic, Z.; Knežević, B.; Dilic, M.; Miličić, D.; Manfrini, O.; Koller, A.; Dorobantu, M.; Badimon, L.; Bugiardini, R. The no-reflow phenomenon in the young and in the elderly. Int. J. Cardiol., 2016, 222, 1122-1128.
[14]
Lim, H.E.; Choi, C.U.; Na, J.O.; Choi, J.I.; Kim, S.H.; Kim, J.W.; Kim, E.J.; Han, S.W.; Park, S.W.; Rha, S.W.; Park, C.G.; Seo, H.S.; Oh, D.J.; Hwang, C.; Kim, Y.H. Effects of iatrogenic myocardial injury on coronary microvascular function in patients undergoing radiofrequency catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol, 2013, 6(2), 318-326.
[15]
Lee, R. Atrial fibrillation and flutter after cardiac surgery., 2016. Avaiable at: https://www.uptodate.com/contents/ atrial-fibrillation-and-flutter-after-cardiac-surgery#H11
[16]
Maisel, W.H.; Rawn, J.D.; Stevenson, W.G. Atrial fibrillation after cardiac surgery. Ann. Intern. Med., 2001, 135(12), 1061-1073.
[17]
Tsikouris, J.P.; Kluger, J.; Song, J.; White, C.M. Changes in P-wave dispersion and P-wave duration after open heart surgery are associated with the peak incidence of atrial fibrillation. Heart Lung, 2001, 30(6), 466-471.
[18]
Dupont, E.; Ko, Y.; Rothery, S.; Coppen, S.R.; Baghai, M.; Haw, M.; Severs, N.J. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation, 2001, 103(6), 842-849.
[19]
Karaca, M.; Demirbas, M.I.; Biceroglu, S.; Cevik, A.; Cetin, Y.; Arpaz, M.; Yilmaz, H. Prediction of early postoperative atrial fibrillation after cardiac surgery: is it possible? Cardiovasc. J. Afr., 2012, 23(1), 34-36.
[20]
Dhurandhar, V.; Saxena, A.; Parikh, R.; Vallely, M.P.; Wilson, M.K.; Butcher, J.K.; Black, D.A.; Tran, L.; Reid, C.M.; Bannon, P.G. Outcomes of on-pump versus off-pump coronary artery bypass graft surgery in the high risk (AusSCORE > 5). Heart Lung Circ., 2015, 24(12), 1216-1224.
[21]
Andrews, T.C.; Reimold, S.C.; Berlin, J.A.; Antman, E.M. Prevention of supraventricular arrhythmias after coronary artery bypass. A meta-analysis of randomized control trial. Circulation, 1991, 84, III236-III244.
[22]
Aranki, S.F.; Shaw, D.P.; Adams, D.H.; Rizzo, R.J.; Couper, G.S.; VanderVliet, M.; Collins, J.J., Jr; Cohn, L.H.; Burstin, H.R. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation, 1996, 94(3), 390-397.
[23]
Creswell, L.L.; Schuessler, R.B.; Rosenbloom, M.; Cox, J.L. Hazards of postoperative atrial arrhythmias. Ann. Thorac. Surg., 1993, 56(3), 539-549.
[24]
Mathew, J.P.; Fontes, M.L.; Tudor, I.C.; Ramsay, J.; Duke, P.; Mazer, C.D.; Barash, P.G.; Hsu, P.H.; Mangano, D.T. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA, 2004, 291(14), 1720-1729.
[25]
Fuller, J.A.; Adams, G.G.; Buxton, B. Atrial fibrillation after coronary artery bypass grafting. Is it a disorder of the elderly? J. Thorac. Cardiovasc. Surg., 1989, 97(6), 821-825.
[26]
Lauer, M.S.; Eagle, K.A.; Buckley, M.J.; DeSanctis, R.W. Atrial fibrillation following coronary artery bypass surgery. Prog. Cardiovasc. Dis., 1989, 31(5), 367-378.
[27]
Wyse, D.G.; Waldo, A.L.; DiMarco, J.P.; Domanski, M.J.; Rosenberg, Y.; Schron, E.B.; Kellen, J.C.; Greene, H.L.; Mickel, M.C.; Dalquist, J.E.; Corley, S.D. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med., 2002, 347(23), 1825-1833.
[28]
Al-Sarraf, N.; Thalib, L.; Hughes, A.; Tolan, M.; Young, V.; McGovern, E. Effect of preoperative atrial fibrillation on postoperative outcome following cardiac surgery. Cardiol. Res. Pract., 2012, 2012, 272384.
[29]
Swartz, M.F.; Fink, G.W.; Lutz, C.J.; Taffet, S.M.; Berenfeld, O.; Vikstrom, K.L.; Kasprowicz, K.; Bhatta, L.; Puskas, F.; Kalifa, J.; Jalife, J. Left versus right atrial difference in dominant frequency, K(+) channel transcripts, and fibrosis in patients developing atrial fibrillation after cardiac surgery. Heart Rhythm, 2009, 6(10), 1415-1422.
[30]
Tanaka, K.; Zlochiver, S.; Vikstrom, K.L.; Yamazaki, M.; Moreno, J.; Klos, M.; Zaitsev, A.V.; Vaidyanathan, R.; Auerbach, D.S.; Landas, S.; Guiraudon, G.; Jalife, J.; Berenfeld, O.; Kalifa, J. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ. Res., 2007, 101(8), 839-847.
[31]
Swartz, M.F.; Fink, G.W.; Sarwar, M.F.; Hicks, G.L.; Yu, Y.; Hu, R.; Lutz, C.J.; Taffet, S.M.; Jalife, J. Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation. J. Am. Coll. Cardiol., 2012, 60(18), 1799-1806.
[32]
He, X.; Gao, X.; Peng, L.; Wang, S.; Zhu, Y.; Ma, H.; Lin, J.; Duan, D.D. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circ. Res., 2011, 108(2), 164-175.
[33]
Li, J.; Yang, Y.; Ng, C.Y.; Zhang, Z.; Liu, T.; Li, G. Association of plasma transforming growth factor-ß1 levels and the risk of atrial fibrillation: a meta-analysis. PLoS One, 2016, 11(5), e0155275.
[34]
Rahmutula, D.; Marcus, G.M.; Wilson, E.E.; Ding, C.H.; Xiao, Y.; Paquet, A.C.; Barbeau, R.; Barczak, A.J.; Erle, D.J.; Olgin, J.E. Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1. Cardiovasc. Res., 2013, 99(4), 769-779.
[35]
Schneider, M.P.; Hua, T.A.; Böhm, M.; Wachtell, K.; Kjeldsen, S.E.; Schmieder, R.E. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J. Am. Coll. Cardiol., 2010, 55(21), 2299-2307.
[36]
Goette, A.; Schön, N.; Kirchhof, P.; Breithardt, G.; Fetsch, T.; Häusler, K.G.; Klein, H.U.; Steinbeck, G.; Wegscheider, K.; Meinertz, T. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol, 2012, 5(1), 43-51.
[37]
January, C.T.; Wann, L.S.; Alpert, J.S.; Calkins, H.; Cigarroa, J.E.; Cleveland, J.C., Jr; Conti, J.B.; Ellinor, P.T.; Ezekowitz, M.D.; Field, M.E.; Murray, K.T.; Sacco, R.L.; Stevenson, W.G.; Tchou, P.J.; Tracy, C.M.; Yancy, C.W. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol., 2014, 64(21), e1-e76.
[38]
Kirchhof, P.; Benussi, S.; Kotecha, D.; Ahlsson, A.; Atar, D.; Casadei, B.; Castella, M.; Diener, H.C.; Heidbuchel, H.; Hendriks, J.; Hindricks, G.; Manolis, A.S.; Oldgren, J.; Popescu, B.A.; Schotten, U.; Van Putte, B.; Vardas, P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J., 2016, 37(38), 2893-2962.
[39]
On, Y.K.; Jeon, E.S.; Lee, S.Y.; Shin, D.H.; Choi, J.O.; Sung, J.; Kim, J.S.; Sung, K.; Park, P. Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. J. Thorac. Cardiovasc. Surg., 2009, 137(6), 1515-1520.
[40]
Kostin, S.; Klein, G.; Szalay, Z.; Hein, S.; Bauer, E.P.; Schaper, J. Structural correlate of atrial fibrillation in human patients. Cardiovasc. Res., 2002, 54(2), 361-379.
[41]
Sackner-Bernstein, J.D. The myocardial matrix and the development and progression of ventricular remodeling. Curr. Cardiol. Rep., 2000, 2(2), 112-119.
[42]
Xu, J.; Cui, G.; Esmailian, F.; Plunkett, M.; Marelli, D.; Ardehali, A.; Odim, J.; Laks, H.; Sen, L. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation, 2004, 109(3), 363-368.
[43]
Liu, Y.; Xu, B.; Wu, N.; Xiang, Y.; Wu, L.; Zhang, M.; Wang, J.; Chen, X.; Li, Y.; Zhong, L. Association of MMPs and TIMPs with the occurrence of atrial fibrillation: a systematic review and meta-analysis. Can. J. Cardiol., 2016, 32(6), 803-813.
[44]
Huxley, R.R.; Lopez, F.L.; MacLehose, R.F.; Eckfeldt, J.H.; Couper, D.; Leiendecker-Foster, C.; Hoogeveen, R.C.; Chen, L.Y.; Soliman, E.Z.; Agarwal, S.K.; Alonso, A. Novel association between plasma matrix metalloproteinase-9 and risk of incident atrial fibrillation in a case-cohort study: The atherosclerosis risk in communities study. PLoS One, 2013, 8(3), e59052.
[45]
Sasaki, N.; Okumura, Y.; Watanabe, I.; Mano, H.; Nagashima, K.; Sonoda, K.; Kogawa, R.; Ohkubo, K.; Nakai, T.; Hirayama, A. Increased levels of inflammatory and extracellular matrix turnover biomarkers persist despite reverse atrial structural remodeling during the first year after atrial fibrillation ablation. J. Interv. Card. Electrophysiol., 2014, 39(3), 241-249.
[46]
Hijazi, Z.; Oldgren, J.; Siegbahn, A.; Granger, C.B.; Wallentin, L. Biomarkers in atrial fibrillation: A clinical review. Eur. Heart J., 2013, 34(20), 1475-1480.
[47]
Wazni, O.M.; Martin, D.O.; Marrouche, N.F.; Latif, A.A.; Ziada, K.; Shaaraoui, M.; Almahameed, S.; Schweikert, R.A.; Saliba, W.I.; Gillinov, A.M.; Tang, W.H.; Mills, R.M.; Francis, G.S.; Young, J.B.; Natale, A. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation, 2004, 110(2), 124-127.
[48]
Gibson, P.H.; Croal, B.L.; Cuthbertson, B.H.; Rae, D.; McNeilly, J.D.; Gibson, G.; Jeffrey, R.R.; Buchan, K.G.; El-Shafei, H.; Hillis, G.S. Use of preoperative natriuretic peptides and echocardiographic parameters in predicting new-onset atrial fibrillation after coronary artery bypass grafting: a prospective comparative study. Am. Heart J., 2009, 158(2), 244-251.
[49]
Sezai, A.; Hata, M.; Niino, T.; Kasamaki, Y.; Nakai, T.; Hirayama, A.; Minami, K. Study of the factors related to atrial fibrillation after coronary artery bypass grafting: a search for a marker to predict the occurrence of atrial fibrillation before surgical intervention. J. Thorac. Cardiovasc. Surg., 2009, 137(4), 895-900.
[50]
Tavakol, M.; Hassan, K.Z.; Abdula, R.K.; Briggs, W.; Oribabor, C.E.; Tortolani, A.J.; Sacchi, T.J.; Lee, L.Y.; Heitner, J.F. Utility of brain natriuretic peptide as a predictor of atrial fibrillation after cardiac operations. Ann. Thorac. Surg., 2009, 88(3), 802-807.
[51]
Gasparovic, H.; Burcar, I.; Kopjar, T.; Vojkovic, J.; Gabelica, R.; Biocina, B.; Jelic, I. NT-pro-BNP, but not C-reactive protein, is predictive of atrial fibrillation in patients undergoing coronary artery bypass surgery. Eur. J. Cardiothorac. Surg., 2010, 37(1), 100-105.
[52]
Masson, S.; Wu, J.H.; Simon, C.; Barlera, S.; Marchioli, R.; Mariani, J.; Macchia, A.; Lombardi, F.; Vago, T.; Aleksova, A.; Dreas, L.; Favaloro, R.R.; Hershson, A.R.; Puskas, J.D.; Dozza, L.; Silletta, M.G.; Tognoni, G.; Mozaffarian, D.; Latini, R. Circulating cardiac biomarkers and postoperative atrial fibrillation in the OPERA trial. Eur. J. Clin. Invest., 2015, 45(2), 170-178.
[53]
Anatoĺevna, R.O.; Veniaminovich, F.O.; Mikhaylovich, K.S. Predictors of new-onset atrial fibrillation in elderly patients with coronary artery disease after coronary artery bypass graft. J. Geriatr. Cardiol., 2016, 13(5), 444-449.
[54]
Ata, Y.; Turk, T.; Ay, D.; Eris, C.; Demir, M.; Ari, H.; Ata, F.; Yavuz, S.; Ozyazicioglu, A. Ability of B-type natriuretic peptide in predicting postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Heart Surg. Forum, 2009, 12(4), E211-E216.
[55]
Cai, G.L.; Chen, J.; Hu, C.B.; Yan, M.L.; Xu, Q.H.; Yan, J. Value of plasma brain natriuretic peptide levels for predicting postoperative atrial fibrillation: a systemic review and meta-analysis. World J. Surg., 2014, 38(1), 51-59.
[56]
Rossi, A.; Enriquez-Sarano, M.; Burnett, J.C., Jr; Lerman, A.; Abel, M.D.; Seward, J.B. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J. Am. Coll. Cardiol., 2000, 35(5), 1256-1262.
[57]
Costello-Boerrigter, L.C.; Boerrigter, G.; Redfield, M.M.; Rodeheffer, R.J.; Urban, L.H.; Mahoney, D.W.; Jacobsen, S.J.; Heublein, D.M.; Burnett, J.C. Jr Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: Determinants and detection of left ventricular dysfunction. J. Am. Coll. Cardiol., 2006, 47(2), 345-353.
[58]
Bruins, P.; te Velthuis, H.; Yazdanbakhsh, A.P.; Jansen, P.G.; van Hardevelt, F.W.; de Beaumont, E.M.; Wildevuur, C.R.; Eijsman, L.; Trouwborst, A.; Hack, C.E. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation, 1997, 96(10), 3542-3548.
[59]
Aviles, R.J.; Martin, D.O.; Apperson-Hansen, C.; Houghtaling, P.L.; Rautaharju, P.; Kronmal, R.A.; Tracy, R.P.; Van Wagoner, D.R.; Psaty, B.M.; Lauer, M.S.; Chung, M.K. Inflammation as a risk factor for atrial fibrillation. Circulation, 2003, 108(24), 3006-3010.
[60]
Worden, J.C.; Asare, K. Postoperative atrial fibrillation: role of inflammatory biomarkers and use of colchicine for its prevention. Pharmacotherapy, 2014, 34(11), 1167-1173.
[61]
Lo, B.; Fijnheer, R.; Nierich, A.P.; Bruins, P.; Kalkman, C.J. C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization. Ann. Thorac. Surg., 2005, 79(5), 1530-1535.
[62]
Paschalis, A.; Tousoulis, D.; Demosthenous, M.; Antonopoulos, A.; Papaioannou, S.; Miliou, A.; Koumallos, N.; Antoniades, C.; Stefanadis, C. Pre-operative inflammation and post-operative atrial fibrillation in coronary artery bypass surgery. Int. J. Cardiol., 2014, 173(2), 327-328.
[63]
Henn, V.; Slupsky, J.R.; Gräfe, M.; Anagnostopoulos, I.; Förster, R.; Müller-Berghaus, G.; Kroczek, R.A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 1998, 391(6667), 591-594.
[64]
Kim, Y.M.; Kattach, H.; Ratnatunga, C.; Pillai, R.; Channon, K.M.; Casadei, B. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J. Am. Coll. Cardiol., 2008, 51(1), 68-74.
[65]
Clermont, G.; Vergely, C.; Jazayeri, S.; Lahet, J.J.; Goudeau, J.J.; Lecour, S.; David, M.; Rochette, L.; Girard, C. Systemic free radical activation is a major event involved in myocardial oxidative stress related to cardiopulmonary bypass. Anesthesiology, 2002, 96(1), 80-87.
[66]
Levy, J.H.; Tanaka, K.A. Inflammatory response to cardiopulmonary bypass. Ann. Thorac. Surg., 2003, 75(2), S715-S720.
[67]
Antoniades, C.; Van-Assche, T.; Shirodaria, C.; Diesch, J.; Antonopoulos, A.S.; Lee, J.; Cunnington, C.; Tousoulis, D.; Stefanadis, C.; Casadei, B.; Taggart, D.; Channon, K.M.; Leeson, P. Preoperative sCD40L levels predict risk of atrial fibrillation after off-pump coronary artery bypass graft surgery. Circulation, 2009, 120(11)(Suppl.), S170-S176.
[68]
Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Simoons, M.L.; Chaitman, B.R.; White, H.D. Third universal definition of myocardial infarction. Nat. Rev. Cardiol., 2012, 9(11), 620-633.
[69]
Moreno, V.; Hernández-Romero, D.; Vilchez, J.A.; García-Honrubia, A.; Cambronero, F.; Casas, T.; González, J.; Martínez, P.; Climent, V.; de la Morena, G.; Valdés, M.; Marín, F. Serum levels of high-sensitivity troponin T: A novel marker for cardiac remodeling in hypertrophic cardiomyopathy. J. Card. Fail., 2010, 16(12), 950-956.
[70]
Hudson, M.P.; O’Connor, C.M.; Gattis, W.A.; Tasissa, G.; Hasselblad, V.; Holleman, C.M.; Gaulden, L.H.; Sedor, F.; Ohman, E.M. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am. Heart J., 2004, 147(3), 546-552.
[71]
Korley, F.K.; Jaffe, A.S. Preparing the United States for high-sensitivity cardiac troponin assays. J. Am. Coll. Cardiol., 2013, 61(17), 1753-1758.
[72]
Latini, R.; Masson, S.; Pirelli, S.; Barlera, S.; Pulitano, G.; Carbonieri, E.; Gulizia, M.; Vago, T.; Favero, C.; Zdunek, D.; Struck, J.; Staszewsky, L.; Maggioni, A.P.; Franzosi, M.G.; Disertori, M. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: Data from the GISSI-atrial fibrillation trial. J. Intern. Med., 2011, 269(2), 160-171.
[73]
Januzzi, J.L., Jr Troponin testing after cardiac surgery. HSR Proc. Intensive Care Cardiovasc. Anesth., 2009, 1(3), 22-32.
[74]
Knayzer, B.; Abramov, D.; Natalia, B.; Tovbin, D.; Ganiel, A.; Katz, A. Atrial fibrillation and plasma troponin I elevation after cardiac surgery: relation to inflammation-associated parameters. J. Card. Surg., 2007, 22(2), 117-123.
[75]
Hernández-Romero, D.; Vílchez, J.A.; Lahoz, Á.; Romero-Aniorte, A.I.; Orenes-Piñero, E.; Caballero, L.; Jara-Rubio, R.; Arribas, J.M.; García-Alberola, A.; Valdés, M.; Lip, G.Y.; Marín, F. High-sensitivity troponin T as a biomarker for the development of atrial fibrillation after cardiac surgery. Eur. J. Cardiothorac. Surg., 2014, 45(4), 733-738.
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
53
6
1